Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

1 Ribociclib is manufactured by Novartis for early breast cancer and advanced or metastatic breast cancer ... The primary efficacy outcome was measured by the invasive disease-free survival that led ...

Here we report the final results for overall survival ... breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) or placebo every 3 weeks plus ...

At the time of final iDFS analysis, iDFS at 36 months was 90.7% (95% CI, 89.3-91.8) in the ribociclib plus NSAI arm and 87.6% (95% CI, 86.1-88.9) in the NSAI arm. Overall survival data were ...

The invasive disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA approval of Kisqali for this early breast cancer population, including ...

In MBC, Kisqali has consistently demonstrated statistically significant overall survival benefit across three Phase III trials10-20. The NCCN Guidelines® for breast cancer recommend ribociclib ...

including overall survival. "With this approval, we are redefining treatment options for a broader population of people impacted by breast cancer and facing the persistent risk of recurrence ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant ...